CENTRAL NERVOUS SYSTEM STIMULANT
Fintepla is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat seizures associated with Dravet syndrome in patients at least 2 years old. Fintepla is also referred to by its drug name, fenfluramine.
It is not known exactly how Fintepla works, but recent research suggests that it acts on a specific cell membrane receptor protein common in nerve cells. As an amphetamine derivative, Fintepla is only available through a restricted program called Fintepla REMS.
How do I take it?
Fintepla is an oral solution taken twice daily.
The FDA-approved label for Fintepla lists common side effects including decreased appetite, drowsiness, sedation, lethargy, diarrhea, constipation, abnormal echocardiogram, fatigue, weakness, loss of muscle control, balance and walking problems, increased blood pressure, drooling, fever, upper respiratory tract infection, vomiting, decreased weight, seizures lasting more than 5 minutes, and falling.
Less common but serious side effects for Fintepla can include suicidal ideation and behavior, sedation, elevated serotonin levels (serotonin syndrome), vision impairment (glaucoma), valvular heart disease, and high blood pressure affecting the lungs and heart (pulmonary arterial hypertension).
For more details about this treatment, visit:
Fintlepa — Zogenix
Fintepla (formerly ZX008) — Dravet Syndrome News
We never share your personal information with anyone.